Dec 7, 2011 6:54 AM PST
|
|
NasdaqGS: SGEN Stock Quote
| Last Trade: | 35.74 | Day's Range: | 35.50 - 36.20 | |
| Trade Time: | 3:22pm | 52wk Range: | 17.09 - 39.00 | |
| Change: | -0.01 (-0.03%) | Volume: | 315,346 | |
| Prev Close: | 35.75 | Avg Vol (3m): | 820,286 | |
| Open: | 36.03 | Market Cap: | 4.334B | |
| Bid: | 35.72 x 100 | P/E (ttm): | N/A | |
| Ask: | 35.74 x 100 | EPS (ttm): | -0.486 | |
| 1y Target Est: | 32.42 | Div & Yield: | 0.00 (N/A) |
NasdaqGS: SGEN Overview
Seattle Genetics, Inc. (Seattle Genetics) is a clinical stage biotechnology company focused on the development and commercialization of monoclonal antibody-based therapies for cancer and autoimmune diseases. Its product candidate, brentuximab vedotin (SGN-35), is being developed for the treatment of diseases, which express an antigen called CD30 present on multiple cancer types, including Hodgkin lymphoma and systemic anaplastic large cell lymphoma (sALCL). It also has collaborations for its antibody-drug conjugate (ADC) technology with a range of biotechnology and pharmaceutical companies. In addition, it has four other clinical-stage programs: SGN-75, ASG-5ME, dacetuzumab (SGN-40) and SGN-70. In September 2010, it discontinued its lintuzumab (SGN-33) development program.
Do you know of another great research resource for SGEN that belongs here? Please let us know and provide the URL.
